Drugs / ALT02
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03242239 | Feb → Aug 2016 | — | Alteogen, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALT02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03242239 ↗ |
| Known as | Trastuzumab | “A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects” NCT03242239 ↗ |